Back to search
Leucine-Rich Glioma Inactivated 1 Autoimmune Encephalitis
Clinical trial pipeline · Data from ClinicalTrials.gov
See which Leucine-Rich Glioma Inactivated 1 Autoimmune Encephalitis trials you may qualify forClinical trial pipeline · Data from ClinicalTrials.gov
See which Leucine-Rich Glioma Inactivated 1 Autoimmune Encephalitis trials you may qualify forThe purpose of this study is to assess the efficacy, safety, PK, and PD of satralizumab in participants with NMDAR and LGI1 encephalitis.
Anti-leucine-rich glioma-inactivated 1 (LGI1) encephalitis has been increasingly identified as the second most common type of autoimmune encephalitis after anti…